{"product_id":"allovir-pestle-analysis","title":"Allovir PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic trends, and emerging technologies are reshaping Allovir’s outlook—our concise PESTLE snapshot highlights key external risks and opportunities you can act on today. Ideal for investors, strategists, and advisors, the full PESTLE delivers a complete, editable breakdown with actionable insights. Purchase now to access the in-depth analysis and strengthen your strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Reform and Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernmental shifts in healthcare policy directly influence grant and subsidy flows to late-stage biotech; federal NIH funding for cell therapy research rose to $1.9B in FY2025, benefiting firms like AlloVir.\u003c\/p\u003e\n\u003cp\u003eAs of late 2025, debates over Medicare expansion for advanced cell therapies—estimated to affect coverage for therapies priced \u0026gt;$200k—are pivotal to AlloVir’s commercial outlook.\u003c\/p\u003e\n\u003cp\u003eChanges in administration or Congress can swiftly alter reimbursement incentives and BARDA\/NIH grant priorities, materially impacting funding for T-cell research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Agency Influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe political climate around FDA and EMA oversight affects orphan drug approval speed; FDA granted 1,200+ orphan designations in 2023, highlighting prioritization that can accelerate Allovir's multi-virus T-cell pathways.\u003c\/p\u003e\n\u003cp\u003eHeightened political pressure to serve immunocompromised populations has increased breakthrough therapy grants by ~15% between 2021–2024, potentially shortening review timelines for Allovir.\u003c\/p\u003e\n\u003cp\u003eConversely, intensified scrutiny on drug pricing — with US congressional hearings in 2024 and EU cost-containment measures targeting high-priced biologics — could prompt regulators to impose tighter efficacy and safety evidentiary requirements before market entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Trade and Sourcing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGeopolitical tensions (e.g., US-China export controls) disrupt supply chains for biological samples and cryogenic equipment, raising shipping lead times by up to 30% and spiking costs; AlloVir reported supply-chain inflation pressures across 2024–2025 with reagent price increases ~12–18% in industry averages. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePublic Health Policy Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGovernment pandemic preparedness and viral surveillance programs, with global spending on pandemic preparedness rising to an estimated $28 billion in 2024, bolster demand for anti-viral immunity firms like Allovir.\u003c\/p\u003e\n\u003cp\u003ePolitical emphasis on protecting vulnerable groups, including roughly 200,000 annual solid-organ transplant patients in the US and EU, keeps VST therapies prioritized in national health plans.\u003c\/p\u003e\n\u003cp\u003eRegulatory policies often yield expedited regulatory pathways and funding mechanisms for life-threatening viral therapies, with expedited review programs reducing approval times by up to 30% in 2023–2025 data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePublic funding growth: ~$28B global pandemic preparedness (2024)\u003c\/li\u003e\n\u003cli\u003eTarget populations: ~200,000 annual transplant patients (US\/EU)\u003c\/li\u003e\n\u003cli\u003eRegulatory impact: expedited reviews cut approval time ~30% (2023–2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property Legislation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical debates on patent reform and biologics exclusivity (currently 12 years in the US per 42 U.S.C. 262(k) protections) could erode AlloVir’s competitive edge by shortening protection for T-cell platforms.\u003c\/p\u003e\n\u003cp\u003ePolicy moves to boost biosimilar entry—FDA issued 40+ biosimilar approvals through 2024—may compress AlloVir’s long-term revenue from proprietary therapies.\u003c\/p\u003e\n\u003cp\u003eAlloVir must actively engage in policy, secure robust patents, and safeguard manufacturing trade secrets amid shifting legislative pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS biologics exclusivity: 12 years; biosimilar approvals: 40+ by 2024\u003c\/li\u003e\n\u003cli\u003ePatent reform risk: shorter exclusivity reduces lifetime revenue\u003c\/li\u003e\n\u003cli\u003eStrategy: strengthen patents, trade-secret protection, policy advocacy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising govt funding and faster approvals boost AlloVir amid reimbursement and biosimilar risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGovernment funding for cell therapy rose (NIH cell therapy grants $1.9B FY2025) and pandemic preparedness ~$28B (2024), improving AlloVir’s R\u0026amp;D tailwinds, while Medicare coverage debates for \u0026gt;$200k therapies and drug-pricing scrutiny (US hearings 2024) threaten reimbursement; expedited pathways cut approval times ~30% (2023–25), but patent\/exclusivity reform and biosimilar approvals (40+ by 2024) pose long-term revenue risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH cell therapy funding\u003c\/td\u003e\n\u003ctd\u003e$1.9B (FY2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePandemic preparedness\u003c\/td\u003e\n\u003ctd\u003e$28B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpedited review impact\u003c\/td\u003e\n\u003ctd\u003e~30% faster (2023–25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar approvals\u003c\/td\u003e\n\u003ctd\u003e40+ by 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect the Allovir across Political, Economic, Social, Technological, Environmental, and Legal dimensions, with data-driven insights and forward-looking scenario implications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Allovir's PESTLE into a crisp, shareable summary that highlights external risks and opportunities for quick alignment in meetings or client reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccess to Capital Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe high-rate environment at end-2025—US 10-year at ~4.2% and Fed funds around 5.25%—raises AlloVir’s cost of debt and equity, increasing discount rates used in valuations for clinical-stage firms.\u003c\/p\u003e\n\u003cp\u003eInvestor appetite for high-risk biotech remains selective: 2024–25 VC biotech funding fell ~18% YoY and IPOs dropped 60% from 2021 peaks, constraining secondary financing for AlloVir.\u003c\/p\u003e\n\u003cp\u003eEconomic downturns can sharply reduce venture and follow-on activity; with cash burn trends, AlloVir must manage runway tightly—targeting 12–18 months of liquidity—to avoid dilutive emergency raises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement Frameworks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eReimbursement for off-the-shelf T-cell therapies is critical: payers must cover prices that reflect high manufacturing costs—average CAR-T list prices reached about $475,000–$525,000 per treatment in 2024—while enabling ROI for developers like Allovir. Payer willingness hinges on demonstrated real-world effectiveness and cost offsets; a 2023 ICER analysis showed required durable survival gains to justify current price points. Hospital budget constraints—U.S. inpatient drug spending rose ~10% in 2023—could slow adoption unless therapies prove long-term savings in reduced readmissions and chronic care costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Scalability and Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTransitioning from clinical- to commercial-scale manufacturing demands substantial capital—biomanufacturing facilities often cost $100–300M to build and AlloVir’s off-the-shelf T-cell platform seeks better economies of scale versus autologous therapies, potentially lowering per-dose costs by 40–60% at scale. Initial capex remains high, with estimated single-product fabs requiring $50–150M. Inflation in 2024–25 raised specialized labor costs ~6–8% and raw material prices 5–12%, compressing gross margins unless offset by volume-driven COGS reductions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Economic Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eFluctuations in currency exchange rates—EUR\/USD volatility of about 8% in 2024—raise costs for AlloVir’s international clinical trials and compress future global revenue margins.\u003c\/p\u003e\n\u003cp\u003eEconomic instability in markets like Brazil and parts of EU, where GDP growth slowed to ~1% in 2024, may defer adoption of advanced immunotherapies as health systems prioritize essential care.\u003c\/p\u003e\n\u003cp\u003eAlloVir must hedge currency exposure and diversify funding to mitigate risks across trial sites and protect projected net revenue streams.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEUR\/USD volatility ~8% (2024)\u003c\/li\u003e\n\u003cli\u003eGDP growth ~1% in lagging markets (2024)\u003c\/li\u003e\n\u003cli\u003eHedge FX and diversify funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket Competition and Valuation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe cell therapy market is highly competitive with multiple firms targeting transplant-related indications; AlloVir’s 2025 implied market cap estimates ranged widely, reflecting sensitivity to trial milestones for viral-specific T cells.\u003c\/p\u003e\n\u003cp\u003eValuation swings with clinical news—positive Phase 2 data historically lifted peers by 20–40%—and broader biotech index moves (NASDAQ Biotechnology Index down ~15% in 2022–2023) have caused volatility in AlloVir’s stock, constraining M\u0026amp;A options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh competition in transplant cell therapies\u003c\/li\u003e\n\u003cli\u003eValuation tied to clinical milestones and addressable market size\u003c\/li\u003e\n\u003cli\u003eBiotech index volatility (~-15% 2022–23) impacts strategic flexibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigher rates, tighter VC\/IPO funding, capex \u0026amp; pricing pressure squeeze AlloVir risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigher 2024–25 rates (US 10y ~4.2%, Fed funds ~5.25%) raise AlloVir’s WACC, while 2024–25 VC biotech funding fell ~18% YoY and IPOs down ~60%, tightening follow-on financing; manufacturing capex ~$50–150M per fab and CAR‑T list prices ~$475–525k pressure pricing; EUR\/USD ~8% volatility and GDP ~1% in lagging markets add revenue\/cost risks.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024–25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS 10y \/ Fed funds\u003c\/td\u003e\n\u003ctd\u003e~4.2% \/ ~5.25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC biotech funding YoY\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIPOs vs 2021\u003c\/td\u003e\n\u003ctd\u003e-60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFab capex\u003c\/td\u003e\n\u003ctd\u003e$50–150M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAR‑T list price\u003c\/td\u003e\n\u003ctd\u003e$475–525k\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEUR\/USD volatility\u003c\/td\u003e\n\u003ctd\u003e~8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGDP (lagging markets)\u003c\/td\u003e\n\u003ctd\u003e~1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAllovir PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Allovir PESTLE document you’ll receive after purchase—fully formatted, professionally structured, and ready to use; no placeholders or surprises. What you see in the preview is the final file available for instant download post-checkout, including all sections, analyses, and visuals as displayed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751340388729,"sku":"allovir-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/allovir-pestle-analysis.png?v=1772230404","url":"https:\/\/growthsharematrix.com\/products\/allovir-pestle-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}